TriangleNCT04162873 · OUTCOME
Assessment of Overall Pain Control and Management for Patients on Celecoxib Compared to Placebo - Pain Control Questionnaire.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- score on the pain control questionnaire
- Interval / dispersion
- Standard Deviation
- Time frame
- post-surgery (up to 29 days from surgery) and end of treatment (up to 5 months from surgery)
What was measured
Patient satisfaction was assessed with a pain control questionnaire. The participants were asked questions about their pain satisfaction over the last seven days. The pain control questionnaire was scored from 0-100, with smaller values indicating poor pain control satisfaction and larger values indicating excellent pain control satisfaction. This outcome was assessed at post-surgery and end of treatment for up to 5 months
Analysis population: One participant on the Celcoxib Arm was not evaluable for this endpoint.
Groups in this outcome
Celecoxib Arm
Patients received celecoxib PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity. Celecoxib: Given PO or via feeding tube Quality-of-Life Assessment: Ancillary studies Questionnaire Administration: Ancillary studies
Placebo Arm
Patients received placebo PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity. Placebo: Given PO or via feeding tube Quality-of-Life Assessment: Ancillary studies Questionnaire Administration: Ancillary studies
| Group | Source count |
|---|---|
| Celecoxib Arm | 4 |
| Placebo Arm | 7 |
Reported measurements
Post-Operation
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Celecoxib Arm | 79.86 | 17.77 | Not reported | Not reported | Not reported |
| Placebo Arm | 96.82 | 5.42 | Not reported | Not reported | Not reported |
End of Treatment
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Celecoxib Arm | 80.55 | 21.52 | Not reported | Not reported | Not reported |
| Placebo Arm | 88.89 | 13.61 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 17.77
- value
- 79.86
- group Id
- OG001
- spread
- 5.42
- value
- 96.82
- title
- Post-Operation
- categories
- measurements
- group Id
- OG000
- spread
- 21.52
- value
- 80.55
- group Id
- OG001
- spread
- 13.61
- value
- 88.89
- title
- End of Treatment
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 7
- units
- Participants
- description
- Patient satisfaction was assessed with a pain control questionnaire. The participants were asked questions about their pain satisfaction over the last seven days. The pain control questionnaire was scored from 0-100, with smaller values indicating poor pain control satisfaction and larger values indicating excellent pain control satisfaction. This outcome was assessed at post-surgery and end of treatment for up to 5 months
- dispersion Type
- Standard Deviation
- groups
- description
- Patients received celecoxib PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity. Celecoxib: Given PO or via feeding tube Quality-of-Life Assessment: Ancillary studies Questionnaire Administration: Ancillary studies
- id
- OG000
- title
- Celecoxib Arm
- description
- Patients received placebo PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity. Placebo: Given PO or via feeding tube Quality-of-Life Assessment: Ancillary studies Questionnaire Administration: Ancillary studies
- id
- OG001
- title
- Placebo Arm
- param Type
- MEAN
- population Description
- One participant on the Celcoxib Arm was not evaluable for this endpoint.
- reporting Status
- POSTED
- time Frame
- post-surgery (up to 29 days from surgery) and end of treatment (up to 5 months from surgery)
- title
- Assessment of Overall Pain Control and Management for Patients on Celecoxib Compared to Placebo - Pain Control Questionnaire.
- type
- SECONDARY
- unit Of Measure
- score on the pain control questionnaire
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice